Cambridge Investment Research Advisors, Inc. Provention Bio, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$6.7 - $24.21 $9,681 - $34,983	-1,445 Reduced 4.83%	28,450 $686,000
Q4 2022 Feb 08, 2023	BUY	$4.52 - $10.57 $62,827 - $146,923	13,900 Added 86.9%	29,895 $316,000
Q1 2022 May 12, 2022	SELL	$3.4 - $7.88 $1,360 - $3,152	-400 Reduced 2.44%	15,995 $117,000
Q4 2021 Feb 03, 2022	SELL	$5.59 - $7.39 $17,329 - $22,909	-3,100 Reduced 15.9%	16,395 $92,000
Q3 2021 Nov 02, 2021	BUY	$5.66 - $8.33 $17,546 - $25,823	3,100 Added 18.91%	19,495 $124,000
Q2 2021 Aug 10, 2021	SELL	$6.71 - $11.04 $12,078 - $19,872	-1,800 Reduced 9.89%	16,395 $138,000
Q1 2021 May 07, 2021	BUY	$10.12 - $19.45 $32,333 - $62,142	3,195 Added 21.3%	18,195 $190,000
Q4 2020 Feb 04, 2021	BUY	$11.79 - $18.94 $4,716 - $7,576	400 Added 2.74%	15,000 $254,000
Q3 2020 Oct 29, 2020	SELL	$10.34 - $15.2 $5,170 - $7,600	-500 Reduced 3.31%	14,600 $187,000
Q2 2020 Jul 27, 2020	BUY	$7.81 - $17.0 $117,931 - $256,700	15,100 New	15,100 $213,000

Others Institutions Holding PRVB

# of Institutions

Shares Held

170K

Call Options Held

Put Options Held

Odey Asset Management Group LTD London, X0

170K
Shares

$0
1.36% of portfolio

View Full List

About Provention Bio, Inc.

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

More about PRVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account